Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Not available
- Industry
- Not available
- ISIN
- GG00BD3FV870
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 26029.2
- Dividend yield
- 0.0%
- Beta
- -0.06
About
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Visit company website
5 years, 5 months ago
OKYO Pharma Limited is currently in a long term downtrend where the price is trading 25.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 0.0% to $-435K since the same quarter in the previous year.
Finally, its free cash flow grew by 47.9% to $-215K since the same quarter in the previous year.
Based on the above factors, OKYO Pharma Limited gets an overall score of 2/5.